• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疟原虫抗原特异性白细胞介素-10和抗体反应可预测恶性疟原虫疟疾中疟原虫清除加速。

Parasite antigen-specific interleukin-10 and antibody reponses predict accelerated parasite clearance in Plasmodium falciparum malaria.

作者信息

Luty A J, Lell B, Schmidt-Ott R, Lehman L G, Luckner D, Greve B, Matousek P, Herbich K, Schmid D, Ulbert S, Migot-Nabias F, Dubois B, Deloron P, Kremsner P G

机构信息

University of Tübingen, Institute for Tropical Medicine, Department of Parasitology, Wilhelmstrasse 27, 72074 Tübingen, Germany. Tel: (+49) 7071 2980228, Fax: (+49) 7071 295189, e-mail: adrian.

出版信息

Eur Cytokine Netw. 1998 Dec;9(4):639-46.

PMID:9889408
Abstract

Using strict inclusion criteria, we conducted a hospital-based, case-control study in which 100 Gabonese children with severe Plasmodium falciparum malaria were matched for age, gender and provenance with 100 children presenting with mild malaria. Parasite antigen-specific cellular and humoral immunological responses were measured and compared with post-treatment parasite clearance times in each group. Significantly faster parasite clearance times were associated with in vitro production of IL-10 by acute-phase peripheral blood mononuclear cells (PBMC) in response to both liver and asexual stage parasite antigens, but not with proliferative, IFN-gamma, or TNF responses to the same antigens. In addition, in those children with mild malaria, higher levels of acute-phase antibody responses to liver stage antigen-1 (LSA-1) were associated with faster parasite clearance times, and were correlated with the presence of IL-10 responses to the same antigen. No such associations were found for IL-10 or antibody responses to a range of asexual blood stage antigens. Those with severe malaria had significantly lower levels of anti-LSA-1 antibodies compared to their counterparts with mild malaria. In conclusion, the results of this study suggest that parasite antigen-specific IL-10-mediated antibody responses may play a role in the control of asexual stage parasite multiplication in P. falciparum malaria.

摘要

我们采用严格的纳入标准,开展了一项基于医院的病例对照研究,将100名患有严重恶性疟原虫疟疾的加蓬儿童,按照年龄、性别和来源与100名患有轻度疟疾的儿童进行匹配。检测了寄生虫抗原特异性细胞免疫和体液免疫反应,并与每组治疗后的寄生虫清除时间进行比较。寄生虫清除时间显著加快与急性期外周血单核细胞(PBMC)在体外对肝脏期和无性期寄生虫抗原产生白细胞介素-10(IL-10)有关,但与对相同抗原的增殖反应、γ干扰素(IFN-γ)或肿瘤坏死因子(TNF)反应无关。此外,在那些患有轻度疟疾的儿童中,对肝脏期抗原-1(LSA-1)的急性期抗体反应水平较高与寄生虫清除时间较快有关,并且与对相同抗原的IL-10反应的存在相关。对于一系列无性血液期抗原的IL-10或抗体反应未发现此类关联。与患有轻度疟疾的儿童相比,患有严重疟疾的儿童抗LSA-1抗体水平显著较低。总之,本研究结果表明,寄生虫抗原特异性IL-10介导的抗体反应可能在控制恶性疟原虫疟疾无性期寄生虫增殖中发挥作用。

相似文献

1
Parasite antigen-specific interleukin-10 and antibody reponses predict accelerated parasite clearance in Plasmodium falciparum malaria.疟原虫抗原特异性白细胞介素-10和抗体反应可预测恶性疟原虫疟疾中疟原虫清除加速。
Eur Cytokine Netw. 1998 Dec;9(4):639-46.
2
Plasmodium falciparum liver-stage antigen-1 peptide-specific interferon-gamma responses are not suppressed during uncomplicated malaria in African children.在非洲儿童的非复杂性疟疾期间,恶性疟原虫肝期抗原-1肽特异性干扰素-γ反应未受到抑制。
Eur Cytokine Netw. 2001 Oct-Dec;12(4):647-53.
3
Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children.干扰素-γ反应与非洲幼儿对恶性疟原虫再感染的抵抗力相关。
J Infect Dis. 1999 Apr;179(4):980-8. doi: 10.1086/314689.
4
Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.一种重组疟疾候选疫苗(恶性疟原虫AMA-1胞外结构域的I+II结构域,来自印度恶性疟原虫等位基因)的免疫原性。
Vaccine. 2008 Aug 18;26(35):4526-35. doi: 10.1016/j.vaccine.2008.06.031. Epub 2008 Jun 30.
5
Malaria blood-stage infection and its control by the immune system.疟疾血液阶段感染及其免疫系统的控制。
Folia Biol (Praha). 2000;46(6):210-8.
6
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.重组肝期抗原-1(LSA-1)与 AS01 或 AS02 联合使用是安全的,可引发高滴度抗体并诱导 IFN-γ/IL-2 CD4+T 细胞,但不能预防实验性疟原虫感染。
Vaccine. 2010 Jul 12;28(31):5135-44. doi: 10.1016/j.vaccine.2009.08.046. Epub 2009 Sep 6.
7
Comparison of cellular and humoral responses to recombinant protein and synthetic peptides of exon2 region of Plasmodium falciparum erythrocyte membrane protein1 (PfEMP1) among malaria patients from an endemic region.来自疟疾流行地区的疟疾患者对恶性疟原虫红细胞膜蛋白1(PfEMP1)外显子2区域重组蛋白和合成肽的细胞和体液反应比较
Parasitol Int. 2007 Mar;56(1):51-9. doi: 10.1016/j.parint.2006.11.003. Epub 2007 Jan 25.
8
Selected problems of malaria blood stage immunity.疟疾血液阶段免疫的选定问题。
Tokai J Exp Clin Med. 1998 Apr;23(2):55-62.
9
Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area.疟疾高度流行地区居民对恶性疟原虫肝期抗原-1和血小板反应蛋白相关黏附蛋白的干扰素-γ和白细胞介素-10应答的稳定性
Am J Trop Med Hyg. 2006 Apr;74(4):585-90.
10
Plasmodium falciparum-specific interleukin-2 and tumor necrosis factor-alpha expressing-T cells are associated with resistance to reinfection and severe malaria in healthy African children.表达恶性疟原虫特异性白细胞介素-2和肿瘤坏死因子-α的T细胞与健康非洲儿童抵抗再次感染及严重疟疾有关。
Eur Cytokine Netw. 2004 Jul-Sep;15(3):189-96.

引用本文的文献

1
Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria.疟原虫 LSA1 和 LSAP2 融合抗原的病毒载体的临床前开发和评估,以提高抗肝期疟疾的疗效。
Infect Immun. 2020 Jan 22;88(2). doi: 10.1128/IAI.00573-19.
2
Immunogenicity of glycosylphosphatidylinositol-anchored micronemal antigen in natural Plasmodium vivax exposure.天然感染疟原虫 vivax 后糖基磷脂酰肌醇锚定微线抗原的免疫原性。
Malar J. 2017 Aug 22;16(1):348. doi: 10.1186/s12936-017-1967-9.
3
Behavioural and neurological symptoms accompanied by cellular neuroinflammation in IL-10-deficient mice infected with Plasmodium chabaudi.
感染恰氏疟原虫的白细胞介素-10缺陷小鼠出现行为和神经症状,并伴有细胞性神经炎症。
Malar J. 2016 Aug 24;15(1):428. doi: 10.1186/s12936-016-1477-1.
4
Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.对编码十种疟疾抗原的疫苗载体的比较评估确定了两种具有保护作用的肝期候选疫苗。
Sci Rep. 2015 Jul 3;5:11820. doi: 10.1038/srep11820.
5
Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria.婴儿中无并发症和严重恶性疟原虫疟疾的促炎细胞因子和调节细胞因子及趋化因子。
Clin Exp Immunol. 2011 Nov;166(2):218-26. doi: 10.1111/j.1365-2249.2011.04474.x.
6
Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.加纳北部卡萨纳-南卡纳地区儿童的多种疟疾候选疫苗抗原的抗体水平与临床疟疾发作的关系。
Malar J. 2011 May 1;10:108. doi: 10.1186/1475-2875-10-108.
7
Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen 1 and thrombospondin-related adhesive protein immunodominant epitopes in a highland population from Western Kenya.肯尼亚西部高地人群中,γ干扰素和白细胞介素-10对恶性疟原虫肝期抗原1及血小板反应蛋白相关黏附蛋白免疫显性表位应答的稳定性
Am J Trop Med Hyg. 2009 Sep;81(3):489-95.
8
Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.在恒河猴中对由恶性疟原虫肝期抗原1与佐剂AS01B组成的疫苗单独或与RTS,S/AS01B疫苗同时给药时的安全性和免疫原性进行临床前评估。
Infect Immun. 2008 Jan;76(1):229-38. doi: 10.1128/IAI.00977-07. Epub 2007 Oct 22.
9
Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.小鼠对肝期抗原1蛋白FMP011(一种疟疾疫苗候选物)与佐剂AS01B或AS02A联合使用时的免疫反应。
Infect Immun. 2007 Feb;75(2):838-45. doi: 10.1128/IAI.01075-06. Epub 2006 Nov 13.
10
Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum.恶性疟原虫基于红细胞前期蛋白的疫苗——肝期抗原1的工艺开发与分析
Infect Immun. 2005 Apr;73(4):2109-15. doi: 10.1128/IAI.73.4.2109-2115.2005.